<DOC>
	<DOCNO>NCT01163838</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability repeat dos RN316 eligible healthy volunteer . RN316 investigational drug currently study cholesterol lower therapy .</brief_summary>
	<brief_title>Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>LDLC must great equal 130 mg/dl BMI must 18.5 40 kg/m2 History cardiovascular cerebrovascular event past year . Poorly control type 1 type 2 diabetes mellitus Subjects take lipid lower therapy within last 3 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>LDL</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
</DOC>